Get the Stockscreener App
1,064.15
1.67%
-18.05
After Hours:
1065.62
1.47
+0.14%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,064.15, with a volume of 2.40M.
It is down -1.67% in the last 24 hours and up +10.47% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,082.20
Open:
$1067.37
24h Volume:
2.40M
Relative Volume:
0.78
Market Cap:
$948.95B
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
38.30
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
-0.06%
1M Performance:
+10.47%
6M Performance:
+1.72%
1Y Performance:
+42.43%
1-Day Range:
$1,052.15
$1,078.22
1-Week Range:
$1,052.15
$1,149.10
52-Week Range:
$623.78
$1,149.10
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,064.15 | 965.04B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
222.89 | 538.04B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
215.40 | 376.20B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
115.65 | 284.45B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
177.45 | 278.70B | 60.48B | 10.40B | 8.05B | 3.3297 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly and Co stock (US5324571083): shares ease after recent gains as investors digest Q1 momentu - AD HOC NEWS
Hanmi Pharm lands $1.2 bn Lilly licensing deal for gut disorder drug - KED Global
Eli Lilly (LLY) Halts 340B Discounts for Non-Compliant Hospitals - GuruFocus
Eli Lilly issues data sharing ultimatum to 340B hospitals - BioPharma Dive
Eli Lilly (LLY) Showcases Key Data at European Hematology Association Meeting - GuruFocus
Eli Lilly Wins Back CVS Health, Reverting Novo's Advantage - MarketBeat
Eli Lilly and Company’s (LLY) Foundayo and Zepbound Set To Be Covered for Millions of Americans - Insider Monkey
Is Eli Lilly and Company (LLY) Expanding Into Next-Gen Vaccines With $1.55B Acquisition? - Insider Monkey
Lilly to present hematology data at EHA meeting in June - Investing.com
State Street's Health Care ETF Tops Invesco's on Yield and Returns - The Motley Fool
Eli Lilly Reportedly Shuts HK Branch, Lays Off 50 Employees - AASTOCKS.com
Hanmi Pharmaceutical jumps on Eli Lilly tech transfer deal in South KoreaCHOSUNBIZ - Chosunbiz
Korea Investment & Securities lifts Hanmi target after Lilly tech dealCHOSUNBIZ - Chosunbiz
Eli Lilly scores a first in major pharma milestone - thestreet.com
Novo Nordisk A/S Stock (NVO) Closed Down by 3.41% on Jun 1: Key Drivers Unveiled - TradingKey
Eli Lilly (LLY) Expands Licensing Agreement with Camurus for Car - GuruFocus
Hanmi, Haisco win billion-dollar partnerships with Eli Lilly - BioWorld News
These 8 Words From Eli Lilly's CEO Have Wall Street Turning Bullish - Yahoo Finance
Eli Lilly (LLY) Expands Collaboration with Camurus on Amylin Rec - GuruFocus
Eli Lilly and Company (LLY): One of the Top Stocks to Buy Right Now According to AI - Insider Monkey
Lilly expands Camurus partnership to include amylin drugs - Investing.com
Lilly expands Camurus partnership to include amylin drugs By Investing.com - Investing.com Canada
Unit of China's Haisco, Eli Lilly sign collaboration, licensing deals - Reuters
Pharma M&A Roundup: Servier Acquiring Edgewise Therapeutics' Muscular Dystrophy Business, Hanmi Enters Licensing Agreement with Eli Lilly, Avenzo Enters Merger Agreement with Rallybio - PharmExec.com
Haisco, Lilly Strike Drug Development Deal - Contract Pharma
Wegovy pill maintains GLP-1 lead over Lilly rival, but weekly growth slows - Proactive Investors
Is LLY Overvalued? DCF Says Worth $762 - GuruFocus
Is Eli Lilly Starting an Nvidia-Style Run? - The Motley Fool
Haisco Announces Licensing and Research Collaboration Agreement with Lilly to Develop Innovative Medicines Across Multiple Therapeutic Areas - TradingView
Lilly and Hanmi sign $1.26bn licensing deal for sonefpeglutide - Pharmaceutical Technology
Eli Lilly and Company (LLY) Stock Analysis: Evaluating a Pharmaceutical Giant with a 9.96% Upside Potential - DirectorsTalk Interviews
Eli Lilly announces Phase 3 Libretto-432 trial of Retevmo met primary endpoint - Yahoo Finance
Eli Lilly Signs Up to $1.26 Billion Licensing Deal with Hanmi Pharmaceutical for Rare Intestinal Disease Candidate - Korea IT Times
Hanmi Signs Lilly Deal Worth 1.8 Trillion Won - Businesskorea
Hanmi Signs Licensing Deal with Lilly for sonefpeglutide (LAPSGLP-2 analog) - PR Newswire
Hanmi Pharm Co Enters License Agreement With Eli Lilly For Sonefpeglutide - TradingView
Hanmi Pharmaceutical is soaring on the news that it has signed a license agreement for bio-new drug - 매일경제
Pfizer inks $10.5B oncology deal as Lilly expands vaccines - MSN
Eli Lilly (LLY) Reports Positive Phase 3 Trial Results for Retev - GuruFocus
Why Eli Lilly (LLY) stock is trading up today - MSN
Can S&P 500 Access Expansion Drive Eli Lilly Obesity Growth? - Kalkine Media
Is Expanded PBM Access to Obesity Drugs Altering The Investment Case For Eli Lilly (LLY)? - simplywall.st
Eli Lilly Stock (LLY) Opinions on Q1 Earnings Surge and Obesity Drug Approval - Quiver Quantitative
Eli Lilly's Retevmo Cuts Lung Cancer Recurrence Risk By 83% In Phase 3 Trial - NDTV Profit
Eli Lilly (LLY) Reports Promising Results for Retevmo in Lung Ca - GuruFocus
Lilly drug cuts risk of early-stage RET-positive lung cancer returning by 83% - Stock Titan
Eli Lilly and Company Trade Ideas — BVL:LLYUS - TradingView
Eli Lilly and Company (LLY): A Long Term Stock to Buy - Yahoo Finance
Lilly's New Drug Just Delivered the Largest Weight Loss Ever Seen in a Clinical Trial -- Here's What It Means for Investors - The Motley Fool
Stock Split Watch: Is Eli Lilly Next? - Yahoo Finance
LLY Stock Quote Price and Forecast - CNN
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.28%
1.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):